Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cell Structure Alteration”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Early research (Phase 1)Study completedNCT03817125
What this trial is testing

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention

Who this might be right for
Metastatic Melanoma
Parker Institute for Cancer Immunotherapy 14
Early research (Phase 1)Looking for participantsNCT05787587
What this trial is testing

PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+6 more
IDEAYA Biosciences 216
Not applicableApproved For MarketingNCT03906331
What this trial is testing

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Who this might be right for
Non Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+4 more
Eli Lilly and Company
Early research (Phase 1)Active Not RecruitingNCT05222802
What this trial is testing

Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

Who this might be right for
Glioblastoma Multiforme
Katmai Pharmaceuticals Inc. 52
Testing effectiveness (Phase 2)Looking for participantsNCT04040205
What this trial is testing

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Who this might be right for
ChondrosarcomaOsteosarcomaSoft Tissue Sarcoma
Medical College of Wisconsin 44
Testing effectiveness (Phase 2)Looking for participantsNCT06239272
What this trial is testing

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Who this might be right for
Adipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+6 more
St. Jude Children's Research Hospital 139
Early research (Phase 1)Ended earlyNCT05242822
What this trial is testing

Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Who this might be right for
Solid Tumor, AdultIntrahepatic CholangiocarcinomaUrothelial Carcinoma
Kinnate Biopharma 54
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Testing effectiveness (Phase 2)Looking for participantsNCT06669117
What this trial is testing

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Who this might be right for
Solid TumorMET Alteration
Pierre Fabre Medicament 140
Early research (Phase 1)Active Not RecruitingNCT04913285
What this trial is testing

Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Who this might be right for
Solid Tumor, AdultNon-small Cell Lung CancerMelanoma
Pierre Fabre Medicament 400
Large-scale testing (Phase 3)Looking for participantsNCT07218380
What this trial is testing

Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Who this might be right for
Carcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 450
Testing effectiveness (Phase 2)Study completedNCT04939662
What this trial is testing

Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects

Who this might be right for
Lung Cancer
Se-Hoon Lee 25
Testing effectiveness (Phase 2)Ended earlyNCT05267106
What this trial is testing

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

Who this might be right for
GlioblastomaAdult-type Diffuse Gliomas
Incyte Corporation 83
Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Testing effectiveness (Phase 2)Looking for participantsNCT07192068
What this trial is testing

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

Who this might be right for
Non-Small Cell Lung CancerSarcomaHead &Amp; Neck Cancer+2 more
UNICANCER 105
Testing effectiveness (Phase 2)Ended earlyNCT04161391
What this trial is testing

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Who this might be right for
Non Small Cell Lung CancerMedullary Thyroid CancerRET Gene Mutation+2 more
Turning Point Therapeutics, Inc. 41
Testing effectiveness (Phase 2)Study completedNCT05253807
What this trial is testing

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Incyte Corporation 8
Early research (Phase 1)Active Not RecruitingNCT05241834
What this trial is testing

LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Who this might be right for
Carcinoma, Non-Small-Cell LungThyroid Neoplasms
Eli Lilly and Company 70
Testing effectiveness (Phase 2)UnknownNCT01083719
What this trial is testing

A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.

Who this might be right for
Glioblastoma
Medanta Institute of Clinical Research 15
Not applicableStudy completedNCT05036239
What this trial is testing

Recovery From 50 Eccentric Biceps Curls in Young, Untrained Men and Women

Who this might be right for
RecoveryMuscle DamageMuscle Stiffness+2 more
Norwegian School of Sport Sciences 15
Load More Results